Tenofovir exposure in utero and linear growth in HIV-exposed, uninfected infants

AIDS

Volumn 31, Issue 1, 2017, Pages 97-103

  Le Roux, Stanzi M ^a   Jao, Jennifer ^b,c   Brittain, Kirsty ^a   Phillips, Tamsin K ^a   Olatunbosun, Seun ^a   Ronan, Agnes ^a   Zerbe, Allison ^d   Abrams, Elaine J ^d,e   Myer, Landon ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b University of Cape Town ^*  (South Africa)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d Icahn School of Medicine at Mount Sinai ^*  (United States)

^e Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Growth; Infant; Maternal exposure; South Africa; Tenofovir

Indexed keywords

EFAVIRENZ; EMTRICITABINE; LAMIVUDINE; NEVIRAPINE; TENOFOVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ARTICLE; BREAST FEEDING; COHORT ANALYSIS; DRUG EXPOSURE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; MAJOR CLINICAL STUDY; POSTNATAL GROWTH; PREGNANT WOMAN; PRENATAL EXPOSURE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PUERPERIUM; SOUTH AFRICA; STUNTING; TREATMENT DURATION; VIRUS LOAD; YOUNG ADULT; ANTHROPOMETRY; BODY HEIGHT; CHILD DEVELOPMENT; FETOMATERNAL TRANSFUSION; MALE; NEWBORN; PREGNANCY; PREGNANCY COMPLICATION; PROSPECTIVE STUDY;

ADULT; ANTHROPOMETRY; ANTI-HIV AGENTS; BODY HEIGHT; CHILD DEVELOPMENT; FEMALE; HIV INFECTIONS; HUMANS; INFANT; INFANT, NEWBORN; MALE; MATERNAL-FETAL EXCHANGE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PRENATAL EXPOSURE DELAYED EFFECTS; PROSPECTIVE STUDIES; SOUTH AFRICA; TENOFOVIR; YOUNG ADULT;

EID: 84991512003     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000001302     Document Type: Article

References (30)

1. WHO.Global health sector response to HIV, 2000-2015. Focus on innovations in Africa: progress report. 2015.http://apps. who.int/iris/bitstream/10665/198065/1/9789241509824-eng.pdf. [Accessed 18 April 2016].
2. Grant PM, Cotter AG. Tenofovir and bone health. Curr Opin HIV AIDS 2016; 11:326-332.
3. Siberry GK, Williams PL, Mendez H, Seage GR 3rd, Jacobson DL, Hazra R, et al. Safety of tenofovir use during pregnancy: early growth outcomes in HIV-exposed uninfected infants. AIDS 2012; 26:1151-1159.
4. Siberry GK, Jacobson DL, Kalkwarf HJ, Wu JW, DiMeglio LA, Yogev R, et al. Lower newborn bone mineral content associated with maternal use of tenofovir disoproxil fumarate during pregnancy. Clin Infect Dis 2015; 61:996-1003.
5. Siberry G, C. T, Stranix-Chibanda L, Marr C, Shepherd JA, Browning R, et al. Impact of maternal tenofovir use on HIVexposed newborn bone mineral. Session title Prevention and Treatment of Pediatric HIV infections, Session number O-3, Abstract #36. Presented at the Conference on Retroviruses and Opportunistic Infections (CROI). Boston, Massachusetts; 2016.
6. Moran CA, Weitzmann MN, Ofotokun I. The protease inhibitors and HIV-associated bone loss. Curr Opin HIV AIDS 2016; 11:333-342.
7. Jao J, Abrams EJ, Phillips T, Petro G, Zerbe A, Myer L. In utero tenofovir exposure is not associated with fetal long bone growth. Clin Infect Dis 2016; 62:1604-1609.
8. Myer L, Phillips TK, Zerbe A, Ronan A, Hsiao NY, Mellins CA, et al. Optimizing antiretroviral therapy (ART) for maternal and child health (MCH): rationale and design of the MCH-ART study. J AIDS 2016; 72 (Suppl 2):S189-S196.
9. PAWC. PMTCT clinical guidelines update. 2013. https://www.westerncape.gov.za/assets/departments/health/wcp-2013-pmtct-clinical-guidelines-update-final-replacement-2.pdf. [Accessed 6 October 2016].
10. WHO. WHO Multicentre Growth Reference Study Group. WHO child growth standards: length/height-for-age, weightfor-age, weight-for-length, weight-for-height and body mass index-for-age: methods and development. 2006. http://www.who. int/childgrowth/standards/technical-report/en/. [Accessed 2 May 2016].
11. Fenton TR, Nasser R, Eliasziw M, Kim JH, Bilan D, Sauve R. Validating the weight gain of preterm infants between the reference growth curve of the fetus and the term infant. BMC Pediatr 2013; 13:92.
12. Prendergast AJ, Humphrey JH. The stunting syndrome in developing countries. Paediatr Int Child Health 2014; 34:250-265.
13. Kuhn L, Kasonde P, Sinkala M, Kankasa C, Semrau K, Scott N, et al. Does severity of HIV disease in HIV-infected mothers affect mortality and morbidity among their uninfected infants? Clin Infect Dis 2005; 41:1654-1661.
14. Brittain K, Mellins CA, Phillips T, Zerbe A, Abrams EJ, Myer L, et al. Social support, stigma and antenatal depression among HIV-infected pregnant women in South Africa. AIDS Behav 2016. Epub ahead of print. DOI: https://dx.doi.org/10.1007/s10461-016-1389-7.
15. WHO. AUDiT. The Alcohol Use Disorders Identification Test. Guidelines for Use in Primary Care. 2nd Edition. World Health Organization Department of Mental Health and Substance Dependence. 2001. http://apps.who.int/iris/bitstream/10665/67205/1/WHO-MSD-MSB-01.6a.pdf. [Accessed 23 June 2016].
16. Liotta G, Floridia M, Andreotti M, Jere H, Sagno JB, Marazzi MC, et al. Growth indices in breastfed infants pre and postnatally exposed to tenofovir compared with tenofovir-unexposed infants. AIDS 2016; 30:525-527.
17. Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MD, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004; 292:191-201.
18. Gibb DM, Kizito H, Russell EC, Chidziva E, Zalwango E, Nalumenya R, et al. Pregnancy and infant outcomes among HIV-infected women taking long-term art with and without tenofovir in the DART trial. PLoS Med 2012; 9:e100121http://journals.plos.org/plosmedicine/article?id = 10.1371/journal. pmed.1001217 [Accessed 3 July 2016].
19. Pintye J, Langat A, Singa B, Kinuthia J, Odeny B, Katana A, et al. Maternal tenofovir disoproxil fumarate use in pregnancy and growth outcomes among HIV-exposed uninfected infants in Kenya. Infect Dis Obstet Gynecol 2015; 2015:276851.
20. Said-Mohamed R, Micklesfield LK, Pettifor JM, Norris SA. Has the prevalence of stunting in South African children changed in 40 years? A systematic review. BMC Public Health 2015; 15:534.
21. Black RE, Victora CG, Walker SP, Bhutta ZA, Christian P, de Onis M, et al. Maternal and child undernutrition and overweight in low-income and middle-income countries. Lancet 2013; 382:427-451.
22. March of Dimes, PMNCH, Save the Children, WHO. Born too soon: the global action report on preterm birth. 2012. http://apps. who.int/iris/bitstream/10665/44864/1/9789241503433-eng.pdf?ua=1. [Accessed 3 July 2016].
23. Xiao PL, Zhou YB, Chen Y, Yang MX, Song XX, Shi Y, et al. Association between maternal HIV infection and low birth weight and prematurity: a meta-analysis of cohort studies. BMC Pregnancy Childbirth 2015; 15:246.
24. Wada NI, Jacobson LP, Margolick JB, Breen EC, Macatangay B, Penugonda S, et al. The effect of HAART-induced HIV suppression on circulating markers of inflammation and immune activation. AIDS 2015; 29:463-471.
25. Borges AH, O'Connor JL, Phillips AN, Ronsholt FF, Pett S, Vjecha MJ, et al. Factors associated with plasma IL-6 levels during HIV infection. J Infect Dis 2015; 212:585-595.
26. Dauby N, Goetghebuer T, Kollmann TR, Levy J, Marchant A. Uninfected but not unaffected: chronic maternal infections during pregnancy, fetal immunity, and susceptibility to postnatal infections. Lancet Infect Dis 2012; 12:330-340.
27. Khandaker GM, Zimbron J, Lewis G, Jones PB. Prenatal maternal infection, neurodevelopment and adult schizophrenia: a systematic review of population-based studies. Psychol Med 2013; 43:239-257.
28. Ofotokun I, Titanji K, Vunnava A, Roser-Page S, Vikulina T, Villinger F, et al. Antiretroviral therapy induces a rapid increase in bone resorption that is positively associated with the magnitude of immune reconstitution in HIV infection. AIDS 2016; 30:405-414.
29. Filteau S, Rowland-Jones S. Cytomegalovirus infection may contribute to the reduced immune function, growth, development, and health of HIV-exposed, uninfected African children. Front Immunol 2016; 7:257.
30. Gompels UA, Larke N, Sanz-Ramos M, Bates M, Musonda K, Manno D, et al. Human cytomegalovirus infant infection adversely affects growth and development in maternally HIVexposed and unexposed infants in Zambia. Clin Infect Dis 2012; 54:434-442.